MedTrace Logo

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

NCT07222995 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2900

Last updated 2026-02-05

No results posted yet for this study

Summary

The purpose of this study is to examine how different messages about risk of skin cancer can impact the uptake of skin cancer prevention activities.

Conditions

Interventions

BEHAVIORAL

Precision Prevention Booklet

Precision prevention booklet anchored in their MC1R risk that incorporates gold-standard risk communication strategies, including visual risk representations and simple language.

BEHAVIORAL

Standard Prevention Booklet

Standard materials are similar in content to the precision prevention booklet but without any reference to MC1R risk.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Peter Kanetsky, PhD, MPH · Moffitt Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-10
Primary Completion
2030-10-10
Completion
2030-10-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07222995 on ClinicalTrials.gov